[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.157.73. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,036
Citations 0
Global Health
March 21, 2012

Promising Leishmaniasis Drug

JAMA. 2012;307(11):1129. doi:10.1001/jama.2012.295

A drug being tested to treat African trypanosomiasis (sleeping sickness) shows promise in preclinical trials against visceral leishmaniasis, report Scottish researchers (Wyllie S et al. Sci Transl Med. 2012;4[119]:119re1).

Fexinidazole has been found safe in early clinical trials for African sleeping sickness, a disease caused by the parasite Trypanosoma brucei. Because visceral leishmaniasis is caused by a closely related protozoan parasite, Leishmania donovani, and current treatments for visceral leishmaniasis are less than ideal, scientists tested fexinidazole against leishmaniasis. They gave a daily oral dose of the compound for 5 days to leishmaniasis-infected mice and observed almost complete suppression of infection.

First Page Preview View Large
First page PDF preview
First page PDF preview
×